Supplementary Materials

Supplementary Material for:

The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms

Anna de Breij, Martijn Riool, Robert A. Cordfunke, Nermina Malanovic, Leonie de Boer, Roman I. Koning, Elisabeth Ravensbergen, Marnix Franken, Tobias van der Heijde, Bouke K. Boekema, Paulus H. S. Kwakman, Niels Kamp, Abdelouahab El Ghalbzouri, Karl Lohner, Sebastian A. J. Zaat, Jan W. Drijfhout, Peter H. Nibbering*

*Corresponding author. Email: p.h.nibbering{at}lumc.nl

Published 10 January 2018, Sci. Transl. Med. 10, eaan4044 (2018)
DOI: 10.1126/scitranslmed.aan4044

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Antimicrobial activity of SAAP-145/SAAP-148/SAAP-159 alanine-scanning peptides against S. aureus JAR060131 in PBS and in PBS with 50% human plasma.
  • Fig. S2. Effect of plasma proteins on antimicrobial activity of SAAPs against S. aureus JAR060131.
  • Fig. S3. Release of SAAP-148 from hypromellose gel.
  • Fig. S4. Effect of topical application of mupirocin and chlorohexidine ointment on acute and established human ex vivo skin infections of MRSA and A. baumannii.
  • Fig. S5. Effect of topical application of SAAP-148 ointment on ex vivo human skin.
  • Table S1. Bactericidal activity of peptides in preclinical and clinical development against S. aureus and P. aeruginosa in low-salt buffer.
  • Table S2. Antibiogram of ESKAPE pathogens used in this study.
  • Table S3. Resistance development of S. aureus and E. coli.
  • Table S4. Sequences of peptides in preclinical and clinical development.
  • References (5168)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S5 (Microsoft Excel format). Primary data.